In AD, a range of therapeutic antibodies has been engineered into bispecific antibodies by conjugating them with transporter moieties targeting one of two main receptors: transferrin receptor 1 (TfR1), which in humans normally binds iron-carrying transferrin particles and is highly expressed on brain endothelial cells [65], and the insulin receptor (IR) [66]. Here, TFRC is linked to Alzheimer disease.